|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
01513 LIVZON PHARMA
Nominal 
27.850 +1.250 (+4.699%) | 2024/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | |
| Turnover | 11,812,339 | -4.969% | 12,430,038 | 12,629,579 | 12,063,863 | 10,520,410 |
| Cost of Sales | -- | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- | -- |
| 2024/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | (204,203) | -41.448% | (348,754) | (197,582) | (87,342) | (64,750) | |
| Profit / (Loss) on Disposal | 45,203 | -- | (170) | 861 | 7,035 | (1,072) | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | 9,870 | -83.117% | 58,461 | 61,202 | 39,064 | 1,907 | |
| Profit / (Loss) before Taxation | 2,806,146 | 17.773% | 2,382,667 | 2,330,551 | 2,245,689 | 2,489,436 | |
| Taxation | (501,661) | 3.421% | (485,066) | (374,973) | (293,588) | (358,109) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | (243,389) | -- | 56,050 | (46,170) | (176,418) | (416,416) | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | 2,061,096 | 5.500% | 1,953,651 | 1,909,408 | 1,775,683 | 1,714,910 | |
| 2024/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | |
| Net Finance Costs / (Income) | (155,890) | -42.582% | (271,502) | (268,761) | (70,041) | (103,639) |
| Depreciation & Amortisation | 627,240 | -29.357% | 887,900 | 685,630 | 471,339 | 423,391 |
| Directors' Emoluments | 18,942 | 3.375% | 18,324 | 18,702 | 19,795 | 17,177 |
| 2024/12 - Final | %Chg (Compare to Final) | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| Auditor's Opinion Status | Unqualified | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2024/12 - Final | %Chg (Compare to Final) | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| EPS (cts) | 224.000 | 6.667% | 210.000 | 204.000 | 190.000 | 183.000 |
| DPS (cts) | 110.000 | -- | 135.000 | 160.000 | 130.000 | 125.000 |
| Dividend Payout Ratio (%) | 49.107% | -- | 64.286% | 78.431% | 68.421% | 68.306% |
| Cash flow per share ($) | 3.237 | -- | 3.497 | 2.965 | 2.034 | 2.308 |
| NBV per share ($) | 15.211 | -- | 15.199 | 14.832 | 13.865 | 12.814 |
| Remarks: | Real time quote last updated: 01/04/2025 12:45 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB 2,061,096 |
| %Change | 5.500% |
| EPS / (LPS) | RMB 2.240 |
| NBV Per Share (¥) | RMB 15.211 |